Learn how immunotherapies harness a person’s immune system to fight diseases
Learn more about Aduro’s clinical programs
Download the 2018 Annual Report
September 30, 2019 Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference
September 04, 2019 Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Are you interested in working for a company where interactions are authentic, commitment is high and people excel together?